Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
group_5_presentation_1_-_schizophrenia [2018/02/01 19:58]
saeedkf
group_5_presentation_1_-_schizophrenia [2018/02/02 15:09] (current)
bhattvj [References]
Line 1: Line 1:
 ====== Schizophrenia ====== ====== Schizophrenia ======
  
- {{ :​nintchdbpict000287654150.jpg?​300 |}}+ {{ :​nintchdbpict000287654150.jpg?​300 |}} Retrieved from: http://​fcscortland.org/​schizophrenia
  
 ---- ----
Line 44: Line 44:
  
 ==== Etiology ==== ==== Etiology ====
-Through the complex diagnosis of schizophrenia,​ the causes are not entirely known as to why one would directly be linked to the disorder. Genes and environment have been attributed to a probable cause as 10% of individuals who have a first-degree relative with the individual with schizophrenia. In the case of twins, the likelihood increases to a range from 10-65%. Through research it is shown that schizophrenia is not linked to a single gene in the biology thereby leading into the complexity of the disorder. This leads into the argument of genetic changes such as mutations as a cause for the illness. Other causes include pregnancy and birth complications such as low birth weight, premature labour and asphyxia during birth.+Through the complex diagnosis of schizophrenia,​ the causes are not entirely known as to why one would directly be linked to the disorder. Genes and environment have been attributed to a probable cause as 10% of individuals who have a first-degree relative with the individual with schizophrenia. In the case of twins, the likelihood increases to a range from 10-65%. Through research it is shown that schizophrenia is not linked to a single gene in the biology thereby leading into the complexity of the disorder. Many genes act synergistically resulting in changed neurotransmitter interactions (Harrison, 2014). Genetic risk for schizophrenia comes from changes in the DNA sequences, more specifically single nucleotide polymorphisms (SNPs) and copy number variants (CNVs). Several loci have been observed including CACNA1C which is a L- type calcium channel, DRD2, the dopamine D2 receptor, GRIA1, an AMPA receptor subunit and GRIN2A, a NMDA receptor subunit to name a few (Harrison, 2014). This leads into the argument of genetic changes such as mutations as a cause for the illness. Other causes include pregnancy and birth complications such as low birth weight, premature labour and asphyxia during birth.
  
  
Line 95: Line 95:
 First a plan is set in order to target an optimal strategy for the patient to ensure their symptoms are regulated. The Care Programme Approach is initiated and used by professionals within the mental health services. This plan caters to the symptoms of the individual affected with schizophrenia. Second generation antipsychotics are typically administered as the initial therapy as opposed to first generation as the former presents fewer side extrapyramidal side effects however there are increased metabolic symptoms (Patel et al. 2014). Second generation antipsychotics include aripiprazole,​ olanzapine, paliperidone,​ quetiapine, risperidone and ziprasidone delivered through injection or tablet. Metabolic side effects are an increase in weight, fatigue, cholesterol and blood sugar (Healthwise Staff, 2011). First a plan is set in order to target an optimal strategy for the patient to ensure their symptoms are regulated. The Care Programme Approach is initiated and used by professionals within the mental health services. This plan caters to the symptoms of the individual affected with schizophrenia. Second generation antipsychotics are typically administered as the initial therapy as opposed to first generation as the former presents fewer side extrapyramidal side effects however there are increased metabolic symptoms (Patel et al. 2014). Second generation antipsychotics include aripiprazole,​ olanzapine, paliperidone,​ quetiapine, risperidone and ziprasidone delivered through injection or tablet. Metabolic side effects are an increase in weight, fatigue, cholesterol and blood sugar (Healthwise Staff, 2011).
  
 +======Future Direction======
 +Currently, many experts believe there will not be a universal cure for schizophrenia,​ but rather progress will amount in stages. Clozapine, the most effective antipsychotic to this date, has significant side effects and thus causes patients to be uncompliant. Researchers now are investigating whether other antipsychotic medications can have potent efficacy, and reduced side effects, specifically atypical ones (Beaumont, 2000). It should be noted that atypical medications target receptors other than dopamine D2 receptors. Additionally,​ clozapine and typical current antipsychotics do not target negative symptoms of schizophrenia,​ and thus further research is being targeted at those symptoms (Miyamoto, Miyake, Jarskog, Fleischhacker & Lieberman, 2012). ​
  
 +While treatment through medication has been relatively successful at relieving the burden of positive symptoms, not much is known about this condition. Researchers emphasize the importance of first understanding the pathophysiology,​ then attempting to find the solution. It is believed that both genetics and environment play a role in developing this condition, as well as symptom severity, and as a result, more funding should be directed into this field (van Os, Rutten & Poulton, 2008). Although our progress in this disease appears to be superficial,​ physicians and researchers both believe that more effective treatments are in the near future. Through discoveries,​ not only will schizophrenia be better managed, but also other mental conditions - the once “black box” will be more understood. ​
  
-======Conclusion======+{{:​schizophrenia.pptx|}}
  
 +======References======
  
  
 +Beaumont, G. (2000). Antipsychotics – The Future of Schizophrenia Treatment. Current Medical Research And Opinion, 16(1), 37-42. http://​dx.doi.org/​10.1185/​0300799009117006
  
 +Burton, N. (2012). A Brief History of Schizophrenia. Retrieved January 24, 2018, from https://​www.psychologytoday.com/​blog/​hide-and-seek/​201209/​brief-history-schizophrenia
  
 +Bromet, E. J., & Fennig, S. (1999). Epidemiology and natural history of schizophrenia. Biological psychiatry, 46(7), 871-881.
  
 +Cardno, A. G., & Gottesman, I. I. (2000). Twin studies of schizophrenia:​ from bow‐and‐arrow concordances to star wars Mx and functional genomics. American Journal of Medical Genetics Part A, 97(1), 12-17.
  
 +Deng, C., & Dean, B. (2013). Mapping the pathophysiology of schizophrenia:​ interactions between multiple cellular pathways. Frontiers in cellular neuroscience,​ 7.
 +
 +Frankenburg,​ F. (2018). Schizophrenia:​ Practice Essentials, Background, Pathophysiology. Emedicine.medscape.com. Retrieved 23 January 2018, from https://​emedicine.medscape.com/​article/​288259-overview#​a3
 +
 +Gao, X., Zhang, W., Yao, L., Xiao, Y., Liu, L., Liu, J., ... & Sweeney, J. A. (2017). Association between structural and functional brain alterations in drug-free patients with schizophrenia:​ a multimodal meta-analysis. Journal of psychiatry & neuroscience:​ JPN, 43(1), 160219-160219.
 +
 +Gaughran, F., O'​Neill,​ E., Cole, M., Collins, K., Daly, R. J., & Shanahan, F. (1998). Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophrenia research, 29(3), 263-267.
 +
 +Ginestet, D., Loo, H., & Zarifian, E. (1989). Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry, 1(46), 609.
 +
 +Gong, Q., Lui, S., & Sweeney, J. A. (2015). A selective review of cerebral abnormalities in patients with first-episode schizophrenia before and after treatment. American Journal of Psychiatry, 173(3), 232-243.
 +
 +Harrison, P. (2014). Recent genetic findings in schizophrenia and their therapeutic relevance. Journal Of Psychopharmacology,​ 29(2), 85-96. ​
 +
 +Healthwise Staff (2011). Second-Generation Antipsychotics for Treating Schizophrenia. Michigan Medicine.
 +
 +Karlsgodt, K. H., Sun, D., & Cannon, T. D. (2010). Structural and functional brain abnormalities in schizophrenia. Current directions in psychological science, 19(4), 226-231.
 +
 +Kay, S., Fiszbein, A., & Opler, L. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261-276.
 +Jablensky, A. (2010). The diagnostic concept of schizophrenia:​ its history, evolution, and future prospects. Dialogues in clinical neuroscience,​ 12(3), 271.
 +Learn about what is schizophrenia and schizophrenia treatment options. (2018). Schizophrenia.ca. Retrieved 23 January 2018, from http://​www.schizophrenia.ca/​learn_more_about_schizophrenia.php
 +Lichtenstein,​ Paul, et al. "​Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study."​ The Lancet 373.9659 (2009): 234-239.
 +McDonald, C., & Murray, R. (2000). Early and late environmental risk factors for schizophrenia. Brain Research Reviews, 31(2-3), 130-137.
 +McGuire, P., Howes, O., Stone, J., & Fusarpoli, P. (2008). Functional neuroimaging in schizophrenia:​ diagnosis and drug discovery. Trends In Pharmacological Sciences, 29(2), 91-98.
 +McGrath, J. J., & Sasser, E. S. (2009). New directions in the epidemiology of schizophrenia. Medical Journal of Australia, 190(4), S7.
 +
 +McIntosh, A. M., Owens, D. C., Moorhead, W. J., Whalley, H. C., Stanfield, A. C., Hall, J., ... & Lawrie, S. M. (2011). Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. Biological psychiatry, 69(10), 953-958.
 +
 +Miyamoto, S., Miyake, N., Jarskog, L., Fleischhacker,​ W., & Lieberman, J. (2012). Pharmacological treatment of schizophrenia:​ a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Molecular Psychiatry, 17(12), 1206-1227. http://​dx.doi.org/​10.1038/​mp.2012.47
 +
 +NIMH » Schizophrenia. (2018). Nimh.nih.gov. Retrieved 23 January 2018, from https://​www.nimh.nih.gov/​health/​topics/​schizophrenia/​index.shtml
 +
 +Muller, N., Riedel, M., Hadjamu, M., & Schwarz, M. J. (1999). Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. The American Journal of Psychiatry, 156(4), 634.
 +
 +Patel, K. R., Cherian, J., Gohil, K., & Atkinson, D. (2014). Schizophrenia:​ overview and treatment options. Pharmacy and Therapeutics,​ 39(9), 638.
 +Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia:​ a systematic quantitative review. Biological psychiatry, 63(8), 801-808.
 +
 +Reichenberg,​ A., Rieckmann, N., & Harvey, P. (2005). Stability in schizophrenia symptoms over time: Findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study. Journal Of Abnormal Psychology, 114(3), 363-372.
 +Schizophrenia - CMHA National. (2018). CMHA National. Retrieved 23 January 2018, from https://​cmha.ca/​mental-health/​understanding-mental-illness/​schizophrenia
 +Schizophrenia - Diagnosis and treatment - Mayo Clinic. (2018). Mayoclinic.org. Retrieved 21 January 2018, from https://​www.mayoclinic.org/​diseases-conditions/​schizophrenia/​diagnosis-treatment/​drc-20354449
 +Sigmundsson,​ T., Suckling, J., Maier, M., Williams, S. C., Bullmore, E. T., Greenwood, K. E., ... & Toone, B. K. (2001). Structural abnormalities in frontal, temporal, and limbic regions and interconnecting white matter tracts in schizophrenic patients with prominent negative symptoms. American Journal of Psychiatry, 158(2), 234-243.
 +
 +Snyder, S. (2018). What dopamine does in the brain. PNAS. Retrieved 23 January 2018, from http://​www.pnas.org/​content/​108/​47/​18869.full
 +Spencer, E., & Campbell, M. (1994). Children with Schizophrenia:​ Diagnosis, phenomenology,​ and pharmacotherapy. Schizophrenia Bulletin, 20(4), 713-725.
 +Strous, R. D., & Shoenfeld, Y. (2006). Schizophrenia,​ autoimmunity and immune system dysregulation:​ a comprehensive model updated and revisited. Journal of autoimmunity,​ 27(2), 71-80.
 +
 +van Os, J., & Kapur, S. (2018). Schizophrenia. ScienceDirect. Retrieved 23 January 2018, from http://​www.sciencedirect.com/​science/​article/​pii/​S0140673609609958?​via%3Dihub
 +
 +van Os, J., Rutten, B., & Poulton, R. (2008). Gene-Environment Interactions in Schizophrenia:​ Review of Epidemiological Findings and Future Directions. Schizophrenia Bulletin, 34(6), 1066-1082. http://​dx.doi.org/​10.1093/​schbul/​sbn117
 +
 + 
 +
 + 
Print/export
QR Code
QR Code group_5_presentation_1_-_schizophrenia (generated for current page)